Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.
AuthorsGreen, Melanie M
Hiley, Crispin T
Shanks, Jonathan H
Bottomley, Ian C
West, Catharine M L
Cowan, Richard A
Stratford, Ian J
AffiliationDepartment of Pharmacy and Pharmaceutical Sciences, Coupland III, University of Manchester, Oxford Road, Manchester, UK.
MetadataShow full item record
AbstractPURPOSE: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. METHODS AND MATERIALS: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score > or =6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. RESULTS: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. CONCLUSION: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic or hypoxia-specific agents.
CitationExpression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. 2007, 67 (1):84-90 Int. J. Radiat. Oncol. Biol. Phys.
JournalInternational Journal of Radiation Oncology, Biology, Physics
- Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
- Authors: Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C
- Issue date: 2008 Apr
- The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy.
- Authors: Weber DC, Tille JC, Combescure C, Egger JF, Laouiti M, Hammad K, Granger P, Rubbia-Brandt L, Miralbell R
- Issue date: 2012 Apr 30
- Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix.
- Authors: Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM
- Issue date: 2000 Sep
- Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy.
- Authors: Giralt J, Navalpotro B, Hermosilla E, de Torres I, Espin E, Reyes V, Cerezo L, de las Heras M, Ramon y Cajal S, Armengol M, Benavente S
- Issue date: 2006
- Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
- Authors: Nordby Y, Andersen S, Richardsen E, Ness N, Al-Saad S, Melbø-Jørgensen C, Patel HR, Dønnem T, Busund LT, Bremnes RM
- Issue date: 2015 Nov